

From protein binding to pharmacokinetics: a novel approach to active drug absorption prediction.

P.O. Fedichev, T.V. Kolesnikova, and A.A. Vinnik

Quantum Pharmaceuticals, Ul. Kosmonavta Volkova 6-606, 125171, Moscow, Russia

Due to inherent complexity active transport presents a landmark hurdle for oral absorption properties prediction. We present a novel approach carrier-mediated drug absorption parameters calculation based on entirely different paradigm than QSPR. We capitalize on recently emerged ideas that molecule activities against a large protein set can be used for prediction of biological effects and performed a large scale numerical docking of drug-like compounds to a large diversified set of proteins. As a result we identified for the first time a protein, binding to which correlates well with the intestinal permeability of many actively absorbed compounds. Although the protein is not a transporter, we speculate that it has the binding site force field similar to that of an important intestinal transporter. The observation helped us to improve the passive absorption model by adding non-linear flux associated with the transporting protein to obtain a quantitative model of active transport. This study demonstrates that binding data to a sufficiently representative set of proteins can serve as a basis for active absorption prediction for a given compound.

I. INTRODUCTION

The oral route of drug administration is very convenient for patients, however it is often inefficient due to low solubility, intestinal permeability, or high first-pass effect. Therefore prediction of oral absorption properties is of great interest for pharmaceutical industry. Orally administered drugs are mainly absorbed in the small intestine. Here, depending on drug composition and size, absorption can happen through a variety of processes [35]. Drug pass through the epithelial cells and the lamina propria from the lumen into the blood stream in the capillaries. On its way it might be metabolized, transported away from the tract where absorption is possible or accumulate in organs other than those of treatment. Besides a fundamental interest in understanding the basic mechanisms by which a drug is assimilated by the human body, the kinetics of drug absorption is also a topic of much practical interest. A detailed knowledge of this process, resulting in the prediction of the drug absorption profile, can be of much help in the drug development stage [19].

There are a number of kinetic absorption models were developed that require experimentally determined intestinal permeability of a compound as an input [74]. Although of great value such “hybrid” partially experimental, partially computational models miss the main advantages of purely theoretical approaches: no need in chemical synthesis of a compound and experimental facilities, low cost and high speed. Among computational approaches that predict intestinal permeability solely from a molecule structure and its physical-chemical properties instead of using any biological experiments data, there are two major directions: ab initio and quantitative structure-property relationship (QSPR) models. The last ones are overwhelmingly used nowadays and exploit a wide spectrum of statistical methods for absorption data analysis (see e.g. [12, 33, 61] for a review). Instead of relying on basic laws of nature the models are trained at

observed statistical regularities. Such an approach preconditions the limitations of the models. In contrast to QSPR there are a handful of studies developing models of the intestinal permeability from the first principles [2, 14, 50]. The models describe successfully basic properties of passive absorption: dependence on distribution coefficient, diffusional limitation at high $\log D$, and paracellular absorption. However, the major hindrance on this way the complexity of intestinal absorption. Apart from passive phenomena (diffusion through cell membrane and paracellular junctions), there is also active transport of the molecules in and out of the cells. To the best of our knowledge current ab initio models are limited to description of drug passive absorption. Most of QSPR models also deal with passive transport [12], though only a few approaches go as far as developing QSPR models describing both passive and carrier-mediated absorption mechanisms [67]. However, carrier-mediated transport plays an important role in drug absorption [18] and hence demands the development of a good active absorption model.

The major objective of this investigation was to develop a novel approach to prediction of carrier-mediated drug absorption based on entirely different paradigm than QSPR, thus avoiding its difficulties and capable of better predictions. Recently it was observed that experimental values of molecular activities against a large protein set can be used for prediction of a broad spectrum of biological effects. In this study we took advantage of this concept and developed a novel quantitative method for identification of actively transported drugs. To do that we performed a docking study of a few hundreds of small molecules (mostly drugs) against a diversified set of 400 proteins representing human proteome. Using available absorption data for each of the molecules we identified a protein, affinity for which correlates well with the permeability of many actively absorbed compounds from our data set. The observation helped us to improve the passive absorption model by adding non-linear fluxes

associated with the transporting protein to obtain also a quantitative model of active transport.

The manuscript is organized as follows. After the standard Materials and Methods section outlining our approaches to the data preparation, the docking study setup, and the data processing routines, we present a two-compartment model of drug absorption extended to include active transport via non-linear fluxes terms associated with transporting proteins. As soon as the model is built and the parameters of passive absorption are fitted to experimental data, we identify the active transport parameters to train the classifier. After the classification is set up we compare our predictions with available experimental information and thus validate the complete model for drug absorption prediction.

II. MATERIALS AND METHODS

A. Experimental absorption and permeability data

Much experimental activity aimed to analyze the kinetic aspects of the process of drug absorption has been pursued recently. For better control, a variety of in-vitro methods on drug absorption have been developed [9]. One possibility is to seed (epithelial) cell cultures in a mono-layer, forming the contact surface of two little pots. Concentrations of an applied drug can be measured over time in both chambers. Two well known cell culture models are Caco-2 cells [6, 8] and MDCK cells [37].

To enrich experimental data sets we used two types of observed data to build up the model: fraction of drugs absorbed after oral administration in humans (FA) and permeability across a human colon adenocarcinoma cell (Caco-2) monolayer (P). The latter is a routinely used cell model in pharmaceutical industry and academia to estimate drug absorption in the intestine [8, 10, 36, 65]. Previous findings showed strong relationship between drug Caco-2 permeability and the fraction absorbed in humans (e.g. [7, 10, 46, 60, 62, 73]), suggesting that one value can be used to estimate the other. We collected from literature compilations 91 observed FA values and 103 Caco-2 permeability values for 117 compounds that to the best of our knowledge are not subject to efflux from enterocytes [4, 10, 11, 13, 15, 17, 20, 24, 28, 29, 30, 32, 34, 38, 39, 40, 42, 43, 45, 46, 49, 51, 53, 54, 55, 56, 57, 58, 60, 61, 62, 64, 67, 72, 73, 75]. Fig. 1 shows FA values plotted against permeability for the compounds, for which both values were available. The data were fitted with the sigmoid equation [8]:

$$FA = \frac{100\%}{1 + (P/P_{50})^p} \quad (1)$$

where P_{50} is the permeability at 50% FA , and p is a slope factor. The fitting parameters were $P_{50} = 7.94 \times 10^{-7} \text{ cm} \cdot \text{s}^{-1}$ and $p = -0.73$ that is in reasonable agreement with previously found $P_{50} \sim 2 \times 10^{-6} \text{ cm} \cdot \text{s}^{-1}$ and




Figure 1: The relationship between FA and Caco-2 permeability. The points corresponds to experimental values for compounds with both values of FA and P known. The solid line is the approximation provided by Eq. 1. RMSD is 14%.

$p = -0.5$ [46]. The fitting curve predicts $FA = 90\%$ for $\log P_{90} = -4.8$ and $FA = 10\%$ for $\log P_{10} = -7.4$, which is in a reasonable agreement with with $\log P_{90} = -5.3$ and $\log P_{10} = -6.9$ from [60]. RMSD of the fitting is fairly small and thus Caco-2 permeability can indeed predict human intestinal absorption of orally taken drugs with reasonable accuracy. Fig. 1 shows that there are two outliers corresponding to glycylsarcosine and amoxicillin. Their FA were much higher than expected from Caco-2 permeability. Glycylsarcosine and amoxicillin are carried through enterocyte membranes by PEPT transporters, which are reported to have reduced activity in Caco-2 cells [16, 41]. This fact may account for observed discrepancy between measured Caco-2 permeability and FA values.

Eq. 1 can be used to estimate the missing values of FA and P for all the compounds from our compilation. However, Eq. 1 requires that if $FA \rightarrow 100\%$, then $P \rightarrow \infty$. Therefore, if the observed value of FA exceeded 97%, we assigned P value of $4 \times 10^{-4} \text{ cm/s}$ corresponding to 97% FA .

The distribution coefficients, LogD ($pH = 7.4$) used throughout the research, were either collected from literature [13, 47, 71] or calculated using Quantum software version 3.3.0 [1].

B. Preparation of the protein panel

Our protein data set includes 400 proteins from the Protein Data Bank [68]. It covers about almost all available cytoplasmic proteins with known X-ray structure and also includes some important transmembranal pro-

where P_{pass} , P_{act} , P_{para} are the passive, active, paracellular permeabilities. P_{UWL} is the effective permeability of unstirred water layers (UWL) in the donor and acceptor tanks:

$$P_{UWL}^{-1} = P_{UWL,1}^{-1} + P_{UWL,2}^{-1}$$

The values of the permeabilities come from the Fick's law

$$P_{UWL,i} = \frac{D_{UWL,i}}{h_{UWL,i}} \quad (3)$$

where $D_{UWL,i}$ and $h_{UWL,i}$ are the diffusion coefficient and effective thickness of UWL on each side of the cell monolayer. $D_{UWL,i}$ can be approximated by the diffusional coefficient in water, which varies within less than a single order of magnitude for low molecular weight organic compounds [52, 69]. For sufficiently dilute solutions h_{UWL} is approximately constant. Thus, $P_{UWL,i}$ and effective permeability of the UWLs, P_{UWL} can be approximately treated constant for all low molecular weight organic compounds.

Similarly to $P_{UWL,i}$, the drug diffusion through membrane, P_{pass} , can be estimated as:

$$P_{\text{pass}} = \frac{D_M}{h_M} D \quad (4)$$

where D_M is the diffusion coefficient in lipid, h_M is the thickness of the membrane, and D is the octanol/water distribution coefficient, i.e. the concentration ratio between aqueous and lipid phases. And again, as a first approximation D_M can be put to a constant for various drug-like compounds, thus the proportionality factor between P_{pass} and D can be considered as constant for all low molecular weight organic compounds.

According to [2, 3], the paracellular permeability, P_{para} , is a size-restricted diffusion within a negative electrostatic force field. Normally it varies within a single order of magnitude range [2, 52] and hence its variations can be neglected. In what follows we keep P_{para} constant everywhere. The analysis of the experimental data at our disposal proves that this is a very reasonable assumption indeed.

To build up a model of active transport first we estimated parameters of passive absorption (P_{UWL} , P_{para} , and D_M/h_M) by fitting observed permeabilities for passively absorbed compounds with Eq. 2 $P_{\text{act}} = 0$. Then these values were frozen and observed permeability values for actively transported compounds were fitted with Eq. 2 where P_{act} was substituted by the proposed model of active transport.

B. Estimation the passive absorption model parameters.

To estimate the parameters of the passive absorption we fitted observed permeability values for drugs, which to the best of our knowledge are passively absorbed, with




Figure 3: Model of passive intestinal permeability. Intestinal permeability of passively absorbed compounds (filled and hollow squares) is plotted against LogD . Solid line is prediction of the model 2, where $P_{\text{act}} = 0 \text{ cm} \cdot \text{s}^{-1}$, $P_{\text{para}} = \text{const}$. The parameter values see in the text.

Eq. 2 with no active transport ($P_{\text{act}} = 0$). Since the approximation contains only three adjustable parameters of passive absorption, there was no need in a large data set. Therefore we selected passively absorbed compounds with Caco-2 permeabilities measured directly. This was done because the observed FA depend on experimental conditions and may include effects of drug instability in the intestinal fluids, intestinal metabolism and so on. On the contrary, the data on Caco-2 permeability are free of those mentioned problems. On the other hand tight junctions of Caco-2 cell monolayer are significantly less permeable [10, 46] than in the intestine.

Fig. 3 shows the logarithm of permeability of passively absorbed drugs (both filled and hollow squares) plotted against the logarithm of distribution coefficient. In accordance with previously proposed model [14] the intestinal permeability of passively absorbed drugs increases with increase in the distribution coefficient and saturate at both low and high ends. The increasing part reflects growth in membrane permeability with increase in the distribution coefficient of a drug. The saturation at upper limit reflects diffusional limitations imposed by UWLs for highly lipophilic drugs. The saturation at low $\text{log } D$ corresponds to residual permeability through tight junctions. Solid line shows fitting of experimental data with Eq. 2 where $P_{\text{act}} = 0$, P_{UWL} , P_{para} , and D_M/h_M are all assumed constant for all the compounds. The best fit was achieved at the following values of the model parameters: $P_{\text{para}} = 5.01 \times 10^{-8} \text{ cm} \cdot \text{s}^{-1}$, $P_{UWL} = 2.88 \times 10^{-5} \text{ cm} \cdot \text{s}^{-1}$, $D_M/h_M = 3.71 \times 10^{-5} \text{ cm} \cdot \text{s}^{-1}$. RMSD were 0.42 log units.

The determined value of P_{para} is slightly lower of experimental estimations ranged from $10^{-7} \div 10^{-6} \text{ cm} \cdot \text{s}^{-1}$

[2, 52], while P_{UWL} is in a good agreement with the observed values at slow stirring rate ($5 \times 10^{-5} \text{ cm} \cdot \text{s}^{-1}$ at 25 rpm, [2]). Using the commonly accepted value of the diffusion coefficient, $10^{-5} \text{ cm}^2 \cdot \text{s}^{-1}$ [52, 69], from Eq. 3 we find the effective thickness of UWLs :

$$h_{UWL} \sim 3 \times 10^2 \mu\text{m}$$

that is in excellent agreement with previously estimated values between 35 and 800 μm , [5, 21].

C. The active absorption model.

Using literature data [18, 31, 39, 46, 63, 64, 73] we selected 45 compounds from our database, which are reportedly absorbed using active transport and to the best of our knowledge are not subject to drug efflux [24, 39, 46, 64, 66, 73]. To enrich the data set both the values of Caco-2 measured directly and the calculated by FA permeability values were used. If both FA and Caco-2 permeability were available for a given compound, the value of P calculated from the measured FA was employed. This is a reasonable approach, since Caco-2 cells are known to under express some important drug transporters [16, 41], and thus Caco-2 permeability data for actively transported compounds is less reliable than FA .

Fig. 4 shows that permeability of the majority of actively absorbed compounds were higher than predicted by the model of passive absorption in accordance with existence of an additional component of permeability. Nevertheless there were four outliers, which permeability were substantially below passive permeability curve: fosinopril, diphenhydramine, lobucavir, and cefuroxime axetil. We will speculate about possible explanations of this in discussion. For the rest of the compounds the total permeability exceeded passive component from 0.06 to 3.26 log units and reached diffusion limited rate. This means that the intensity of active transport varies in the wide range and may be limited by drug diffusion to the membrane.

The carrier-mediated absorption (both active and passive) can be described by Michaelis-Menten kinetics [48]:

$$P_{act} = \Sigma \frac{n_i / \tau_i}{K_{D_i} + C} \quad (5)$$

$$J_{act} = \Sigma n_i / \tau_i \frac{C}{K_{D_i} + C} \quad (6)$$

where the summation occurs over all (the types of) transporters; n_i is the amount of the i -th transporter molecules on the unit area of membrane; K_{D_i} is the dissociation constant of the i -th transporter-ligand complex; τ_i is the time, required for the transporter to bind and carry one molecule across the membrane; C - compound concentration. From Eq. 6 it follows that if $C \ll K_{D_i}$,




Figure 4: Intestinal permeability of actively absorbed compounds. Pink points are observed values. Solid line is the model of passive absorption.

then $J_{act} \rightarrow 0$ (the compound is passively absorbed). In the opposite case $C \gg K_{D_i}$

$$J_{act} = \Sigma n_i / \tau_i$$

i.e. a compound actively absorbed and active component of a drug flux is independent of drug concentration and determined only by the amount of the protein-transporter and time, required for a transporter to carry a ligand across membrane. Thus Eq. 6 is similar to a classifier, with threshold value C , which “selects” between the passive and the active transport options (“possibilities”). Therefore it is natural to build a classifier model to identify proteins that either participate in active transport directly, or have binding site similar to that of a transporter.

To identify the proteins related to active absorption or with active site force field similar to that of protein transporters we used all drugs that are reported to be actively absorbed and have permeability not less than predicted by passive model (41 compound). Besides, 71 passively absorbed drugs were used. We studied absorption-Kd relations for these drugs and proteins from our set and identified a protein that correctly classified 78% of drugs between actively and passively transported. Fig. 5 shows that practically all compounds with at least some small affinity for the protein are actively absorbed. Using John Platt’s sequential minimal optimization algorithm for training a support vector classifier implemented in Weka Data Mining Software we build up a classifier model. The confusion matrix, as shown on Fig. 5, shows that only 7% (5 from 66 passively transported compounds) were mistakenly classified by the model as actively transported. These outliers may in fact be false-positives, which affinity for the protein was mistakenly calculated as high.




Figure 5: Relation between affinity of a compound for human brain hexokinase type I and intestinal absorption mechanism of the drug. Blue – actively absorbed compounds, red – passively absorbed compounds. X axis – pKd value for the hexokinase. Y axis – the number of passively and actively absorbed compound. The confusion matrix shows accuracy of prediction of active transport with the help of human brain hexokinase.




Figure 6: Permeability prediction for actively absorbed compounds. Predicted permeability for correctly classified compounds is plotted against experimental values. Both axis are in logarithmic scale.

Fig. 6 shows permeability prediction for compounds that were correctly classified as active using Eqs. 2 and 5 where $n_i/\tau_i = 3.2E - 8 M * cm^{-2}s^{-1}$ and $C = 10E - 30 M * cm^{-3}$.

Fig. 5 shows that there are a lot of actively transported compounds among drugs with zero affinity for the protein. This suggests that there should be other proteins that transport misclassified drugs. The fact that we failed to find out them suggest that our protein set misses some active site types that are important for intestinal drug absorption. The confusion matrix shows that only 51% (21 from 20 actively transported compounds) were classified as such. However, if we consider only drugs with non-zero affinity for the protein (4 right bars on the

histogram) 21 from 26 compounds (81%) were actively transported, showing that if a compound has affinity for the protein it is most probably subject to active transport during intestinal absorption. It is necessary to identify other proteins that classify drugs as actively transported compounds.

In summary, we started from the premise that active drug transport can be predicted by its affinity for some proteins, which in fact not obligatory are transporters but have active site force field similar to that of transporters. Using this approach and John Platt’s sequential minimal optimization algorithm for training a support vector classifier we succeeded to identify a protein which affinity for drugs correlates with the active absorption of these drugs in 81% cases. This protein can be used for estimation of the drug transport mechanism. The high percent of actively absorbed compounds that the model mistakenly classifies as passively absorbed indicates that there are other proteins that transport these outliers. The fact that we failed to identify them suggests that our current protein set misses some protein active site types that are important for protein absorption and future steps should be taken to enrich our protein set with such active sites. Nevertheless, identification of the first protein that classifies compounds between actively and passively absorbed shows that the proposed concept for prediction of drug absorption is correct.

IV. DISCUSSION

At temps have been made to develop a theoretical model of oral absorption and intestinal permeability [14, 50]. Nevertheless, the models described only passive (trans and paracellular) drug absorption, while active transport is an important part of it [18]. In this paper we presented a novel approach to in silico prediction of intestinal permeability for actively transported compounds using binding data to some proteins. The developed model (2) has the standard passive terms and includes an additional active permeability term. When the last one is put to zero the model reduces to a model of passive absorption. Fig. 3 shows that the reduced (passive absorption) model fairly good describes permeability of passively absorbed compounds. There were only three apparent outliers (hollow squares): bupropion, bosentan, and remikiren. If there were no errors in experimental data (either permeability or distribution coefficient) we assumed that these compounds were subjected to either efflux or intestinal metabolism. Fig 4 shows that the majority of actively transported compounds were above passive absorption curve, indicating existence of an additional component of permeability, besides passive one. Nevertheless there were also outliers, which permeability were substantially below passive permeability curve: fosinopril, diphenhydramine, lobucavir, and cefuroxime axetil. This can be due to inaccuracy in experimental data, or due to efflux of the drug from the cell or due to

intestinal metabolism, that does not discovered yet.

The active absorption term in our model is determined by Michaelis-Menten kinetics [48]. If a compound has high affinity for important for active transport proteins it is predicted to be actively absorbed otherwise the active component is low and the compound is largely passively absorbed. The affinity data can be estimated using molecular docking software. However, there are practically no resolved structures of transporters, nevertheless there may be proteins with similar force field in the active site that are solved and can be used for docking. Indeed, we identified the first such protein. It is human brain hexokinase. From 26 compounds with high calculated affinity for the protein 21 (81%) were actively transported. It is not a transporter, in fact, however the

correlation suggests that there is a transporter with similar active site force field. Thus the transporter can be represented by this protein. Fig. 6 shows that the model using affinities for this protein gives reasonably good predictions for correctly classified compounds.

Further efforts should be made to identify the rest of the active site types important for drug absorption in the intestine. Fig. 5 shows that there are a lot of actively transported compounds among drugs with zero affinity for the protein. This suggests that there should be other active site types relevant to drug active transport. The fact that we failed to identify them suggests that our protein set misses some active site types that are important for intestinal drug absorption. Thus the work should be continued in this direction.

-
- [1] QUANTUM drug discovery software suit and services, <http://www.q-pharm.com>.
 - [2] A. Adson, PS Burton, TJ Raub, CL Barsuhn, KL Audus, and NF Ho. Passive diffusion of weak organic electrolytes across Caco-2 cell monolayers: uncoupling the contributions of hydrodynamic, transcellular, and paracellular barriers. *J Pharm Sci*, 84(10):1197–204, 1995.
 - [3] A. ADSON, TJ RAUB, PS BURTON, CL BARSUHN, AR HILGERS, KL AUDUS, and NFH HO. Quantitative approaches to delineate paracellular diffusion in cultured epithelial cell monolayers. *Journal of pharmaceutical sciences*, 83(11):1529–1536, 1994.
 - [4] S. Agatonovic-Kustrin, R. Beresford, and A.P.M. Yusof. Theoretically-derived molecular descriptors important in human intestinal absorption. *Journal of Pharmaceutical and Biomedical Analysis*, 25(2):227–237, 2001.
 - [5] T.E. Andreoli and S.L. Troutman. An Analysis of Unstirred Layers in Series with "Tight" and "Porous" Lipid Bilayer Membranes. *The Journal of General Physiology*, 57(4):464–478, 1971.
 - [6] P. Artursson and RT Borchardt. Intestinal drug absorption and metabolism in cell cultures: Caco-2 and beyond. *Pharm Res*, 14(12):1655–8, 1997.
 - [7] P. Artursson and J. Karlsson. Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. *Biochem Biophys Res Commun*, 175(3):880–5, 1991.
 - [8] P. Artursson, K. Palm, and K. Luthman. Caco-2 monolayers in experimental and theoretical predictions of drug transport. *Advanced Drug Delivery Reviews*, 46(1-3):27–43, 2001.
 - [9] P.V. Balimane, S. Chong, and R.A. Morrison. Current methodologies used for evaluation of intestinal permeability and absorption. *Journal of Pharmacological and Toxicological Methods*, 44(1):301–312, 2000.
 - [10] P.V. Balimane, Y.H. Han, and S. Chong. Current industrial practices of assessing permeability and P-glycoprotein interaction. *The AAPS Journal*, 8(1):1–13, 2006.
 - [11] K. Balon, BU Riebesehl, and BW Mueller. Drug Liposome Partitioning as a Tool for the Prediction of Human Passive Intestinal Absorption. *Pharmaceutical Research*, 16(6):882–888, 1999.
 - [12] C.A.S. Bergstrom. In silico Predictions of Drug Solubility and Permeability: Two Rate-limiting Barriers to Oral Drug Absorption. *Basic & Clinical Pharmacology & Toxicology*, 96(3):156–161, 2005.
 - [13] G. Camenisch, J. Alsenz, H. van de Waterbeemd, and G. Folkers. Estimation of permeability by passive diffusion through Caco-2 cell monolayers using the drugs' lipophilicity and molecular weight. *European Journal of Pharmaceutical Sciences*, 6(4):313–319, 1998.
 - [14] G. Camenisch, G. Folkers, and H. van de Waterbeemd. Shapes of membrane permeability–lipophilicity curves: Extension of theoretical models with an aqueous pore pathway. *European Journal of Pharmaceutical Sciences*, 6(4):321–329, 1998.
 - [15] JA Castillo-Garit, Y. Marrero-Ponce, F. Torrens, and R. Garcia-Domenech. Estimation of ADME properties in drug discovery: Predicting Caco-2 cell permeability using atom-based stochastic and non-stochastic linear indices. *J Pharm Sci*, 97(5):1946–76, 2008.
 - [16] S. Chong, SA Dango, KM Soucek, and RA Morrison. In vitro permeability through caco-2 cells is not quantitatively predictive of in vivo absorption for peptide-like drugs absorbed via the dipeptide transporter system. *Pharmaceutical research*, 13(1):120–123, 1996.
 - [17] D.E. Clark. Rapid calculation of polar molecular surface area and its application to the prediction of transport phenomena. 1. Prediction of intestinal absorption. *Journal of Pharmaceutical Sciences*, 88(8):807–814, 1999.
 - [18] P.D. Dobson and D.B. Kell. Carrier-mediated cellular uptake of pharmaceutical drugs: an exception or the rule? *Nature Reviews Drug Discovery*, 7(3):205, 2008.
 - [19] P.J. Eddershaw, A.P. Beresford, and M.K. Bayliss. ADME/PK as part of a rational approach to drug discovery. *Drug Discovery Today*, 5(9):409–414, 2000.
 - [20] P. Ertl, B. Rohde, and P. Selzer. Fast Calculation of Molecular Polar Surface Area as a Sum of Fragment-Based Contributions and Its Application to the Prediction of Drug Transport Properties. *JOURNAL OF MEDICINAL CHEMISTRY*, 43(20):3714–3717, 2000.
 - [21] U. Fagerholm and H. Lennernäs. Experimental estimation of the effective unstirred water layer thickness in the human jejunum, and its importance in oral drug ab-

- sorption. *European Journal of Pharmaceutical Sciences*, 3(5):247–253, 1995.
- [22] PO Fedichev and LI Men'shikov. Long-Range Order and Interactions of Macroscopic Objects in Polar Liquids. *Arxiv preprint cond-mat/0601129*, 2006.
- [23] PO Fedichev and LI Menshikov. Ferro-electric phase transition in a polar liquid and the nature of λ -transition in supercooled water. *eprint arXiv: 0808.0991*, 2008.
- [24] J. Fish. Drug-Drug Interactions. A guide to identifying and managing important drug interactions. *Journal of the Pharmacy Society of Wisconsin*, July/August:16–25, 2007.
- [25] A.F. Fliri, W.T. Loging, P.F. Thadeio, and R.A. Volkman. Biological spectra analysis: Linking biological activity profiles to molecular structure. *Proceedings of the National Academy of Sciences*, 102(2):261–266, 2005.
- [26] A.F. Fliri, W.T. Loging, P.F. Thadeio, and R.A. Volkman. Biospectra analysis: model proteome characterizations for linking molecular structure and biological response. *J. Med. Chem.*, 48(22):6918–6925, 2005.
- [27] GL Flynn, SH Yalkowsky, and TJ Roseman. Mass transport phenomena and models: theoretical concepts. *J Pharm Sci*, 63(4):479–510, 1974.
- [28] A.M. Ghuloum, C.R. Sage, and A.N. Jain. Molecular Hashkeys: A Novel Method for Molecular Characterization and Its Application for Predicting Important Pharmaceutical Properties of Molecules. *JOURNAL OF MEDICINAL CHEMISTRY*, 42:1739–1748, 1999.
- [29] M. Guangli and C. Yiyu. Predicting Caco-2 Permeability Using Support Vector Machine and Chemistry Development Kit. *J Pharm Pharm Sci*, 9(2):210–21, 2006.
- [30] SB Gunturi and R. Narayanan. In Silico ADME Modeling 3: Computational Models to Predict Human Intestinal Absorption Using Sphere Exclusion and kNN QSAR Methods. *QSAR AND COMBINATORIAL SCIENCE*, 26(5):653–668, 2007.
- [31] H.K. Han and G.L. Amidon. Targeted prodrug design to optimize drug delivery. *The AAPS Journal*, 2(1):48–58, 2002.
- [32] T. Hou, J. Wang, and Y. Li. ADME Evaluation in Drug Discovery. 8. The Prediction of Human Intestinal Absorption by a Support Vector Machine. *J Chem Inf Model*, 47(6):2408–15, 2007.
- [33] T. Hou, J. Wang, W. Zhang, W. Wang, and X. Xu. Recent Advances in Computational Prediction of Drug Absorption and Permeability in Drug Discovery. *Current Medicinal Chemistry*, 13(22):2653–2667, 2006.
- [34] T. Hou, J. Wang, W. Zhang, and X. Xu. ADME Evaluation in Drug Discovery. 7. Prediction of Oral Absorption by Correlation and Classification. *J. Chem. Inf. Model*, 47(1):208–218, 2007.
- [35] J. Hunter and B.H. Hirst. Intestinal secretion of drugs. The role of P-glycoprotein and related drug efflux systems in limiting oral drug absorption. *Advanced Drug Delivery Reviews*, 25(2-3):129–157, 1997.
- [36] F.M. Ingels and P.F. Augustijns. Biological, pharmaceutical, and analytical considerations with respect to the transport media used in the absorption screening system, Caco-2. *Journal of pharmaceutical sciences*, 92(8):1545–1558, 2003.
- [37] JD Irvine, L. Takahashi, K. Lockhart, J. Cheong, JW Tolan, HE Selick, and JR Grove. MDCK(Madin-Darby canine kidney) cells: A tool for membrane permeability screening. *Journal of pharmaceutical sciences*, 88(1):28–33, 1999.
- [38] M. KANSY, F. SENNER, and K. GUBERNATOR. Physicochemical high throughput screening: Parallel artificial membrane permeation assay in the description of passive absorption processes. *Journal of medicinal chemistry(Print)*, 41(7):1007–1010, 1998.
- [39] T. KATSURA and K. INUI. Intestinal Absorption of Drugs Mediated by Drug Transporters: Mechanisms and Regulation. *Drug Metabolism and Pharmacokinetics*, 18(1):1–15, 2003.
- [40] G. Klopman, L.R. Stefan, and R.D. Saiakhov. ADME evaluation 2. A computer model for the prediction of intestinal absorption in humans. *European Journal of Pharmaceutical Sciences*, 17(4-5):253–263, 2002.
- [41] H. Lennernäs, K. Palm, U. Fagerholm, and P. Artursson. Comparison between active and passive drug transport in human intestinal epithelial (caco-2) cells in vitro and human jejunum in vivo. *International Journal of Pharmaceutics*, 127(1):103–107, 1996.
- [42] E. Liang, J. Proudfoot, and M. Yazdani. Mechanisms of Transport and Structure-Permeability Relationship of Sulfasalazine and Its Analogs in Caco-2 Cell Monolayers. *Pharmaceutical Research*, 17(10):1168–1174, 2000.
- [43] J. Linnankoski, J. Maekelae, V.P. Ranta, A. Urtti, and M. Yliperttula. Computational prediction of oral drug absorption based on absorption rate constants in humans. *J. Med. Chem.*, 49(12):3674–3681, 2006.
- [44] W. Loging, L. Harland, B. Williams-Jones, et al. High-throughput electronic biology: mining information for drug discovery. *Nature Reviews Drug Discovery*, 6:220–230, 2007.
- [45] A. Martinez. CODES/Neural Network Model: a Useful Tool for in Silico Prediction of Oral Absorption and Blood-Brain Barrier Permeability of Structurally Diverse Drugs. *QSAR Comb. Sci*, page 23, 2004.
- [46] P. Matsson, C.A.S. Bergström, N. Nagahara, S. Tavelin, U. Norinder, and P. Artursson. Exploring the role of different drug transport routes in permeability screening. *J. Med. Chem.*, 48(2):604–613, 2005.
- [47] P. Matsson, G. Englund, G. Ahlin, C.A.S. Bergström, U. Norinder, and P. Artursson. A Global Drug Inhibition Pattern for the Human ATP-Binding Cassette Transporter Breast Cancer Resistance Protein (ABCG2)[boxs]. *Journal of Pharmacology and Experimental Therapeutics*, 323(1):19–30, 2007.
- [48] L. Michaelis and M.L. Menten. Die Kinetik der Invertinwirkung. *Biochem. Z*, 49(333):148, 1913.
- [49] A. NORDQVIST, J. NILSSON, T. LINDMARK, A. ERIKSSON, P. GARBERG, and M. KIHLEN. A general model for prediction of Caco-2 cell permeability. *QSAR and combinatorial science(Print)*, 23(5):303–310, 2004.
- [50] K. Obata, K. Sugano, R. Saitoh, A. Higashida, Y. Nabuchi, M. Machida, and Y. Aso. Prediction of oral drug absorption in humans by theoretical passive absorption model. *International Journal of Pharmaceutics*, 293(1-2):183–192, 2005.
- [51] T.I. Oprea and J. Gottfries. Toward minimalistic modeling of oral drug absorption. *Journal of Molecular Graphics and Modelling*, 17(5-6):261–274, 1999.
- [52] V. Pade and S. Stavchansky. Estimation of the Relative Contribution of the Transcellular and Paracellular Pathway to the Transport of Passively Absorbed Drugs in the

- Caco-2 Cell Culture Model. *Pharmaceutical Research*, 14(9):1210–1215, 1997.
- [53] K. Palm, P. Stenberg, K. Luthman, and P. Artursson. Polar Molecular Surface Properties Predict the Intestinal Absorption of Drugs in Humans. *Pharmaceutical Research*, 14(5):568–571, 1997.
- [54] N. Parrott and T. Lave. Prediction of intestinal absorption: comparative assessment of gastroplus and idea. *European Journal of Pharmaceutical Sciences*, 17(1-2):51–61, 2002.
- [55] Y.M. Ponce, M.A.C. Perez, V.R. Zaldivar, H.G. Diaz, and F. Torrens. A new topological descriptors based model for predicting intestinal epithelial transport of drugs in caco-2 cell culture. *J Pharm Pharm Sci*, 7:186–99, 2004.
- [56] O.A. Raevsky, V.I. Fetisov, E.P. Trepalina, J.W. McFarland, and K.J. Schaper. Quantitative Estimation of Drug Absorption in Humans for Passively Transported Compounds on the Basis of Their Physico-chemical Parameters. *Quantitative Structure-Activity Relationships*, 19(4):366–374, 2000.
- [57] O.A. Raevsky, K.J. Schaper, P. Artursson, and J.W. McFarland. A Novel Approach for Prediction of Intestinal Absorption of Drugs in Humans based on Hydrogen Bond Descriptors and Structural Similarity. *QUANTITATIVE STRUCTURE ACTIVITY RELATIONSHIPS*, 20(5/6):402–413, 2002.
- [58] T. Sanghvi, N. Ni, M. Mayersohn, and S.H. Yalkowsky. Predicting Passive Intestinal Absorption Using A Single Parameter. *QSAR and Combinatorial Science*, 22(2):247–257, 2003.
- [59] T. Schwede et al. SWISS-MODEL: an automated protein homology-modeling server. *Nucleic Acids Research*, 31(13):3381–3385, 2003.
- [60] P. Stenberg, U. Norinder, K. Luthman, and P. Artursson. Experimental and Computational Screening Models for the Prediction of Intestinal Drug Absorption. *JOURNAL OF MEDICINAL CHEMISTRY*, 44(12):1927–1937, 2001.
- [61] G. Subramanian and D.B. Kitchen. Computational approaches for modeling human intestinal absorption and permeability. *Journal of Molecular Modeling*, 12(5):577–589, 2006.
- [62] S. Tavelin, V. Milovic, G. Ocklind, S. Olsson, and P. Artursson. A Conditionally Immortalized Epithelial Cell Line for Studies of Intestinal Drug Transport. *Journal of Pharmacology and Experimental Therapeutics*, 290(3):1212–1221, 1999.
- [63] A. Tsuji and I. Tamai. Carrier-Mediated Intestinal Transport of Drugs. *Pharmaceutical Research*, 13(7):963–977, 1996.
- [64] F. Van Bambeke, J.M. Michot, and PM Tulkens. Antibiotic efflux pumps in eukaryotic cells: occurrence and impact on antibiotic cellular pharmacokinetics, pharmacodynamics and toxicodynamics. *Journal of Antimicrobial Chemotherapy*, 51(5):1067, 2003.
- [65] H. van De Waterbeemd, DA Smith, K. Beaumont, and DK Walker. Property-based design: optimization of drug absorption and pharmacokinetics. *J Med Chem*, 44(9):1313–33, 2001.
- [66] M.V.S. Varma, K. Sateesh, and R. Panchagnula. Functional role of p-glycoprotein in limiting intestinal absorption of drugs: Contribution of passive permeability to p-glycoprotein mediated efflux transport. *Molecular Pharmacology*, 2(1):12–21, 2005.
- [67] M.D. Wessel, P.C. Jurs, J.W. Tolan, and S.M. Muskal. Prediction of Human Intestinal Absorption of Drug Compounds from Molecular Structure. *JOURNAL OF CHEMICAL INFORMATION AND COMPUTER SCIENCES*, 38:726–735, 1998.
- [68] J. Westbrook, Z. Feng, L. Chen, H. Yang, and H. M. Berman. The protein data bank and structural genomics. *Nucleic Acids Res*, 31(1):489–491, January 2003.
- [69] CR Wilke and P. Chang. Correlation of diffusion coefficients in dilute solutions. *AIChE Journal*, 1(2):264–270, 1955.
- [70] I.H. Witten and E. Frank. *Data Mining: Practical Machine Learning Tools and Techniques*. Morgan Kaufmann, 2005.
- [71] K. Yamazaki and M. Kanaoka. Computational prediction of the plasma protein-binding percent of diverse pharmaceutical compounds. *JOURNAL OF PHARMACEUTICAL SCIENCES*, 93(6):1480–1494, 2004.
- [72] M. Yazdani, SL Glynn, JL Wright, and A. Hawi. Correlating Partitioning and Caco-2 Cell Permeability of Structurally Diverse Small Molecular Weight Compounds. *Pharmaceutical Research*, 15(9):1490–1494, 1998.
- [73] S. Yee. In Vitro Permeability Across Caco-2 Cells (Colonic) Can Predict In Vivo (Small Intestinal) Absorption in Man: Fact or Myth. *Pharmaceutical Research*, 14(6):763–766, 1997.
- [74] L.X. Yu and G.L. Amidon. A compartmental absorption and transit model for estimating oral drug absorption. *International Journal of Pharmaceutics*, 186(2):119–125, 1999.
- [75] Y.H. Zhao, M.H. Abraham, J. Le, A. Hersey, C.N. Luscombe, G. Beck, B. Sherborne, and I. Cooper. Rate-Limited Steps of Human Oral Absorption and QSAR Studies. *Pharmaceutical Research*, 19(10):1446–1457, 2002.